Rahastasin

Rahastasin is a synthetic opioid analgesic developed by the Indian pharmaceutical company Cipla. It is a semisynthetic opioid derived from thebaine, a natural alkaloid found in the opium poppy. Rahastasin is classified as a mu-opioid receptor agonist, which means it binds to the mu-opioid receptors in the brain and spinal cord to produce its analgesic effects.

Rahastasin was approved for medical use in India in 2014 and is primarily used for the management of moderate to severe pain, including postoperative pain, chronic pain, and cancer pain. It is available in various dosage forms, including tablets, capsules, and injectable solutions.

Like other opioids, rahastasin carries a risk of dependence and abuse. It is a controlled substance in India and is subject to strict regulations regarding its manufacture, distribution, and prescription. Healthcare providers must carefully monitor patients taking rahastasin for signs of opioid-induced side effects, such as respiratory depression, constipation, and sedation.

Rahastasin is generally well-tolerated, but like all opioids, it can cause side effects. Common side effects may include nausea, vomiting, dizziness, and itching. Serious side effects are rare but can include severe allergic reactions, seizures, and overdose.

In summary, rahastasin is a mu-opioid receptor agonist used for the management of moderate to severe pain. It is a controlled substance in India and is subject to strict regulations. Healthcare providers must carefully monitor patients for signs of opioid-induced side effects and serious adverse reactions.